title: Predictors of prescription errors involving anticancer chemotherapy agents.
abstract: OBJECTIVE
  The majority of medication errors that harm patients relate to the prescribing process. Our study aimed to identify the predictors of prescription errors involving anticancer chemotherapy agents.
  
  
  METHODS
  All consecutive antineoplastic prescriptions from June 2006 to May 2008 were analysed, with medication errors being captured. Potential risk factors for medication prescribing errors were defined in relation to the patient, chemotherapy regimen and hospital organisation. The relationship between these risk factors and observed medication errors or dose medication errors was assessed by univariate and multivariate logistic-regression analyses.
  
  
  RESULTS
  Among the 17,150 chemotherapy prescriptions, 540 contained at least one error (3.15%). The following independent predictors of risk of medication errors were identified: patients with a body surface area >2m(2) (odds ratio (OR): 1.3, 95% confidence interval (CI) 1.01-1.67, p=0.04), protocols with more than three drugs (OR: 1.91, 95%CI 1.59-2.31, p<0.001), protocols involving carboplatin (OR: 2.33, 95%CI 1.85-2.95, p<0.001), protocols requiring at least one modification by the physician (OR: 1.32, 95%CI 1.09-1.61, p=0.005), inpatient care (OR: 1.58, 95%CI 1.28-1.93, p<0.001) and prescriptions by a resident physician (OR: 1.83, 95%CI 1.50-2.22, p<0.001). The risk of medication dose prescribing errors was significantly associated with three independent factors: protocols involving carboplatin (OR: 4.47, 95%CI 3.45-5.79, p<0.001), protocols with more than three drugs (OR: 2.4, 95%CI 1.92-3.00, p<0.001) and protocols requiring at least one modification (OR: 1.33, 95%CI 1.04-1.69, p=0.02).
  
  
  CONCLUSIONS
  In this epidemiologic study, the independent risk factors identified should be targeted for preventive measures in order to improve anticancer agent prescriptions and reduce the risk of medication errors.
authors.affiliation: Hospices Civils de Lyon, Groupement Hospitalier Sud, Clinical Oncology Pharmacy Department - Université Lyon 1, Ecole Doctorale Interdisciplinaire Sciences Santé, Lyon, France. florence.ranchon@chu-lyon.fr
authors.forename: Florence
authors.initials: F
authors.lastname: Ranchon
authors.forename: Céline
authors.initials: C
authors.lastname: Moch
authors.forename: Benoît
authors.initials: B
authors.lastname: You
authors.forename: Gilles
authors.initials: G
authors.lastname: Salles
authors.forename: Vérane
authors.initials: V
authors.lastname: Schwiertz
authors.forename: Nicolas
authors.initials: N
authors.lastname: Vantard
authors.forename: Emilie
authors.initials: E
authors.lastname: Franchon
authors.forename: Claude
authors.initials: C
authors.lastname: Dussart
authors.forename: Emilie
authors.initials: E
authors.lastname: Henin
authors.forename: Olivier
authors.initials: O
authors.lastname: Colomban
authors.forename: Pascal
authors.initials: P
authors.lastname: Girard
authors.forename: Gilles
authors.initials: G
authors.lastname: Freyer
authors.forename: Catherine
authors.initials: C
authors.lastname: Rioufol
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008508:Medication Errors / Q000517:prevention & control; D008875:Middle Aged; D015999:Multivariate Analysis; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents